Helena Gylling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Helena Gylling has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Tatu A. Miettinen
Department of Medicine, Division of Internal Medicine, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland
20 shared publications T Miettinen
4 shared publications- Maarit Hallikainen
Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland
3 shared publications P. Simonen
3 shared publicationsH. Miettinen
2 shared publications- Juha Seppä
Department of Otorhinolaryngology, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland
2 shared publications
Latest Publications
- Open Access
- 23 September 2011
- Published by Springer Nature in European Journal of Nutrition
- Vol. 51 (5) , 615-622
Serum and lipoprotein sitostanol and non-cholesterol sterols after an acute dose of plant stanol ester on its long-term consumption
Chronic inhibition of cholesterol absorption with large doses of plant stanol esters (staest) alters profoundly cholesterol metabolism, but it is unknown how an acute inhibition with a large staest dose alters the postprandial serum and lipoprotein cholesterol precursor, plant sterol, and sitostanol contents. Hypercholesterolemic subjects, randomly and double-blind divided into control (n = 18) and intervention groups (n = 20), consumed experimental diet without and with staest (plant stanols 8.8 g/day) for 10 weeks. Next morning after a fasting blood sample (0 h), the subjects had a breakfast without or with staest (4.5 g of plant stanols). Blood sampling was repeated 4 h later. Lipoproteins were separated with ultracentrifugation, and sterols were measured with gas–liquid chromatography. In 0-h chylomicrons and VLDL, plant sterols were lower in staest than in controls. Postprandially, cholestenol (cholesterol synthesis marker) was reduced in chylomicrons in staest compared with controls (−0.13 ± 0.04 μg/dL vs. 0.01 ± 0.08 μg/dL, P < 0.05). Staest decreased postprandially avenasterol in chylomicrons (P < 0.05 from 0 h). Sitostanol was high at 0 h by chronic staest in serum and VLDL but not in chylomicrons. Postprandial sitostanol was increased by staest in VLDL only. Chronic cholesterol absorption inhibition with large amount of plant stanol esters decreases plant sterols in triglyceride-rich lipoproteins. Acute plant stanol ester consumption increases sitostanol content in triglyceride-rich lipoproteins but suggests to decrease the risk of plant sterol and plant stanol accumulation into vascular wall by chylomicrons.
- 23 September 2011
- Published by Springer Nature in European Journal of Nutrition
- Vol. 51 (5) , 615-622
Open AccessSerum and lipoprotein sitostanol and non-cholesterol sterols after an acute dose of plant stanol ester on its long-term consumption
Chronic inhibition of cholesterol absorption with large doses of plant stanol esters (staest) alters profoundly cholesterol metabolism, but it is unknown how an acute inhibition with a large staest dose alters the postprandial serum and lipoprotein cholesterol precursor, plant sterol, and sitostanol contents. Hypercholesterolemic subjects, randomly and double-blind divided into control (n = 18) and intervention groups (n = 20), consumed experimental diet without and with staest (plant stanols 8.8 g/day) for 10 weeks. Next morning after a fasting blood sample (0 h), the subjects had a breakfast without or with staest (4.5 g of plant stanols). Blood sampling was repeated 4 h later. Lipoproteins were separated with ultracentrifugation, and sterols were measured with gas–liquid chromatography. In 0-h chylomicrons and VLDL, plant sterols were lower in staest than in controls. Postprandially, cholestenol (cholesterol synthesis marker) was reduced in chylomicrons in staest compared with controls (−0.13 ± 0.04 μg/dL vs. 0.01 ± 0.08 μg/dL, P < 0.05). Staest decreased postprandially avenasterol in chylomicrons (P < 0.05 from 0 h). Sitostanol was high at 0 h by chronic staest in serum and VLDL but not in chylomicrons. Postprandial sitostanol was increased by staest in VLDL only. Chronic cholesterol absorption inhibition with large amount of plant stanol esters decreases plant sterols in triglyceride-rich lipoproteins. Acute plant stanol ester consumption increases sitostanol content in triglyceride-rich lipoproteins but suggests to decrease the risk of plant sterol and plant stanol accumulation into vascular wall by chylomicrons.
- 30 June 2011
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 12 (1) , 137
653 POSTPRANDIAL SERUM SITOSTANOL AND NON-CHOLESTEROL STEROLS AFTER AN ACUTE DOSE OF PLANT STANOL ESTER ON ITS CHRONIC CONSUMPTION
- 30 June 2011
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 12 (1) , 137
653 POSTPRANDIAL SERUM SITOSTANOL AND NON-CHOLESTEROL STEROLS AFTER AN ACUTE DOSE OF PLANT STANOL ESTER ON ITS CHRONIC CONSUMPTION
- 30 December 2010
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 22 (7) , 583-590
Effect of weight loss on inflammation in patients with mild obstructive sleep apnea
- 30 December 2010
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 22 (7) , 583-590
Effect of weight loss on inflammation in patients with mild obstructive sleep apnea
- Open Access
- 1 August 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (8) , 2422-2427
Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study
- 1 August 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (8) , 2422-2427
Open AccessInsulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study
- 30 June 2010
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 11 (2)
P245 VERY HIGH INTAKE OF PLANT STANOL ESTERS. TIME FOR REVISION OF EFFICACY AND SAFETY?
- 30 June 2010
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 11 (2)
P245 VERY HIGH INTAKE OF PLANT STANOL ESTERS. TIME FOR REVISION OF EFFICACY AND SAFETY?
- 1 January 2010
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 6 (3)
The Effects of Plant Stanol Ester in Different Subject Groups
Different food products enriched with plant stanol esters have proved effective and safe as a dietary hypocholesterolaemic tool in about 60 published clinical studies during 15 years on the market. In addition to lowering low-density lipoprotein (LDL) cholesterol by 10% with a dose of 2g/day, plant stanol effectively reduces serum plant sterols and also, in some studies, serum triglycerides. It has been shown to be an effective dietary hypocholesterolaemic agent in adults and children with primary hypercholesterolaemia, in familial hypercholesterolaemia, in coronary subjects and in type 1 and type 2 diabetes. Plant stanol ester can be combined with statin to obtain more powerful serum total and LDL cholesterol reduction. This combination therapy inhibits both cholesterol synthesis and absorption. Plant stanol ester reduced the C-reactive protein (CRP) level in recent studies and, in contrast to ezetimibe, it does not change the LDL particle size. Plant stanol ester consumption tends to reduce the plant sterol contents of arterial wall, and in some, but not all, studies it improves endothelial function, a surrogate marker of pre-clinical atherosclerosis.
- 1 January 2010
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 6 (3)
The Effects of Plant Stanol Ester in Different Subject Groups
Different food products enriched with plant stanol esters have proved effective and safe as a dietary hypocholesterolaemic tool in about 60 published clinical studies during 15 years on the market. In addition to lowering low-density lipoprotein (LDL) cholesterol by 10% with a dose of 2g/day, plant stanol effectively reduces serum plant sterols and also, in some studies, serum triglycerides. It has been shown to be an effective dietary hypocholesterolaemic agent in adults and children with primary hypercholesterolaemia, in familial hypercholesterolaemia, in coronary subjects and in type 1 and type 2 diabetes. Plant stanol ester can be combined with statin to obtain more powerful serum total and LDL cholesterol reduction. This combination therapy inhibits both cholesterol synthesis and absorption. Plant stanol ester reduced the C-reactive protein (CRP) level in recent studies and, in contrast to ezetimibe, it does not change the LDL particle size. Plant stanol ester consumption tends to reduce the plant sterol contents of arterial wall, and in some, but not all, studies it improves endothelial function, a surrogate marker of pre-clinical atherosclerosis.
- 31 December 2009
- Published by Elsevier in Sleep Medicine
- Vol. 10, S81
299 OBESITY AND OBSTRUCTIVE SLEEP APNEA: LIFESTYLE INTERVENTION WITH WEIGHT REDUCTION AS A FIRST LINE TREATMENT
- 31 December 2009
- Published by Elsevier in Sleep Medicine
- Vol. 10, S81
299 OBESITY AND OBSTRUCTIVE SLEEP APNEA: LIFESTYLE INTERVENTION WITH WEIGHT REDUCTION AS A FIRST LINE TREATMENT
- 30 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e344
Abstract: 583 VERY HIGH PLANT STANOL ESTER INTAKE AND SERUM LIPIDS, STEROLS, LIVER FUNCTION TESTS, CAROTENOIDS, AND FAT SOLUBLE VITAMINS
- 30 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e344
Abstract: 583 VERY HIGH PLANT STANOL ESTER INTAKE AND SERUM LIPIDS, STEROLS, LIVER FUNCTION TESTS, CAROTENOIDS, AND FAT SOLUBLE VITAMINS
- 30 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e169
Abstract: 1082 PLANT STANOLS IN ATHEROSCLEROSIS
- 30 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e169
Abstract: 1082 PLANT STANOLS IN ATHEROSCLEROSIS
- 27 March 2003
- Published by Taylor & Francis
- p. 55-62
Overview of Intestinal lipid metabolism